International urology and nephrology · 2025
SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Checa-Ros Ana, Okojie Owahabanun Joshua, Steib Nelia, Bellasi Antonio, Salvador-Martínez Pilar, Fortea Isabel, D'Marco Luis
Аннотация
AIMS: This study aims to evaluate differences in adiposopathy and specific inflammatory biomarkers between type 2 diabetes mellitus (T2DM) and non-T2DM patients across various stages of chronic kidney disease (CKD). In addition, it explores potential pathways through which sodium-glucose cotransporter 2 inhibitors (SGLT2i) impact renal outcomes via adipose tissue.
MATERIALS AND METHODS: An observational prospective study was conducted on 143 CKD patients divided into 2 groups: SGLT2i cohort (n = 31) and standard-of-care (SoC) cohort (n = 112). Clinical and analytical data were collected upon recruitment (T0) as well as after 8 months of follow-up (T8).
RESULTS: At T0, patients under the SGLT2i group showed higher significance for cardiovascular upload versus those in SoC treatment, as well as higher values across several inflammation parameters (IL-6, TNF-α, ferritin). At T8, renal function improved in the SGLT2i group in relation to the SoC, accompanied by a decrease in most inflammatory and adiposopathy biomarkers, mainly leptin. Notably, dapagliflozin use (n = 20) was associated with significantly reduced leptin levels and stabilization of TNF-α concentrations vs. SoC at T8.
CONCLUSION: SGLT2i treatment, and particularly dapagliflozin, modulates both adiposopathy and systemic inflammation while slowing down renal function loss, demonstrating benefits for CKD patients regardless of diabetes status.
MATERIALS AND METHODS: An observational prospective study was conducted on 143 CKD patients divided into 2 groups: SGLT2i cohort (n = 31) and standard-of-care (SoC) cohort (n = 112). Clinical and analytical data were collected upon recruitment (T0) as well as after 8 months of follow-up (T8).
RESULTS: At T0, patients under the SGLT2i group showed higher significance for cardiovascular upload versus those in SoC treatment, as well as higher values across several inflammation parameters (IL-6, TNF-α, ferritin). At T8, renal function improved in the SGLT2i group in relation to the SoC, accompanied by a decrease in most inflammatory and adiposopathy biomarkers, mainly leptin. Notably, dapagliflozin use (n = 20) was associated with significantly reduced leptin levels and stabilization of TNF-α concentrations vs. SoC at T8.
CONCLUSION: SGLT2i treatment, and particularly dapagliflozin, modulates both adiposopathy and systemic inflammation while slowing down renal function loss, demonstrating benefits for CKD patients regardless of diabetes status.